Phase 3Completed
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone
A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy
- Sponsor
- Novartis (Industry)
- Enrollment
- 936 enrolled
- Conditions
- Hypertension
- Interventions
- valsartan/amlodipine
- Ages
- adults, older adults
- Registry
- NCT00171002
Full record on ClinicalTrials.gov
From the registry
This study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication
Primary outcomes
- Change from baseline in diastolic blood pressure after 8 weeks
History
Last registry update
Registered
Primary completion
Started